RxDoctor Payments Data

Cynthia Luna-Salazar, MD

Nephrology · Harlingen, TXNPI 1598967366

Payments from drug & device makers

$308in general payments, 2019–2025

Across 17 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$94
  • Boehringer Ingelheim$84
  • Bayer$33
  • Vifor Pharma, Inc.$30
  • Fresenius USA Marketing, Inc.$25
  • Akebia Therapeutics Inc$25
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$28392%
  • Education$258%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$308 in reported general payments places this provider in the 15th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$393,601
Medicare patients
505
Services billed
6,202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin278$247,271
OzempicSemaglutide194$228,967
MounjaroTirzepatide157$172,358
VelphoroSucroferric Oxyhydroxide32$93,550
JanuviaSitagliptin Phosphate70$75,617
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog51$43,523
AuryxiaFerric Citrate15$43,152
LinzessLinaclotide47$41,185
EliquisApixaban28$38,023
TrulicityDulaglutide24$36,821
FarxigaDapagliflozin Propanediol43$34,780
XareltoRivaroxaban27$31,920
KerendiaFinerenone37$29,142
VeltassaPatiromer Calcium Sorbitex25$27,024
MyrbetriqMirabegron23$22,947

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$84$254,536291 claims
Lilly USA, LLCMounjaro, Trulicity$94$209,179181 claims
Fresenius USA Marketing, Inc.Velphoro$25$93,55032 claims
Akebia Therapeutics IncAuryxia$25$43,15215 claims
BayerKerendia$33$29,14237 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 1,070 nephrology providers in Texas.

Other nephrology in Harlingen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →